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Abstract 
 
Periodontitis biomarker research is driven by mainly two targets: to discover biomarkers which can 
identify “at risk” patients before actual bone and periodontal tissue destruction occurs and to build 
up the knowledge of understanding this complex disease with the purpose of finding new drug 
targets.  Whilst previously systemic blood samples and local GCF samples were the analytes of 
choice, recently saliva has gained more attention as an easy and readily accessible oral fluid, with 
many advantages over GCF and blood. The aim of this paper is to give a comprehensive overview of 
the current literature of salivary cytokines in periodontitis, highlighting extensively studied cytokines 
such as IL-1β and IL-6, but also cytokines such as HGF which only have been the target of few studies 
and which warrant further investigation. Salivary cytokines are considered in both cross-sectional 
and longitudinal studies and their potential as a salivary periodontitis biomarker is evaluated against 
criteria of what marks a robust biomarker. Finally, this evaluation will expand to include how robust 
these salivary biomarkers are in light of confounding factors such as systemic diseases and smoking.  
I Introduction 
 
Despite numerous advances in diseases with comparable etiology such as rheumatoid arthritis, 
periodontitis is still only diagnosed once oral tissue and bone destruction has occurred. There is 
therefore a definite need for developing biomarkers for an earlier detection of the disease and to 
further understanding of the underlying complex cytokine patterns in order to develop new drug 
targets.  
Most commonly, cytokines are considered as “hormones” of the immune system e.g. a soluble 
factor produced by one cell which acts on another cell (Dinarello, 2007). However, as Dinarello 
(2007) highlights, hormones are more associated with being products of whole organs rather than 
individual cells and certain cytokines are never secreted and have intracellular functions.  Thus, not 
only classic “cytokines” such as interleukins can be considered, but the range of cytokines can be 
extended to include for example chemokines, growth factors, adipokines, acute phase proteins or 
MMPs. All these molecules have signalling capacities in one way or another, often acting in an 
autocrine and/or paracrine manner. Importantly, there signalling pathways often overlap or merge, 
building a complex network resulting in a high signalling redundancy in the immune system. In the 
following, the term “cytokine” will be used in this broad context. The reader is reminded that 
salivary MMPs and TIMPs are reviewed in another chapter of this issue. 
Functions and applications of cytokines  
As “messengers” of the immune system, cytokines have a multitude of functions. For example, they 
facilitate wound healing, act against pathogens and cancer but also are vital in cell lineage 
developments and embryogenesis. Clinically relevant, some cytokines are either used as drugs or 
drug targets for treatment of a variety of conditions. For example, targeting TNF-α in rheumatoid 
arthritis is a recognized treatment for this autoimmune disorder and IL-2 and interferons have been 
successfully applied in cancer treatment.  
Apart from their use as drugs or drug targets, cytokines have received much attention for causing life 
threatening conditions such as sepsis and multiple organ failure. One of the most well-known 
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examples of the detrimental effects of cytokines is the phase 1 clinical trial of TGN1412, a 
monoclonal antibody targeting the T-cell receptor CD28 (Suntharalingam et al., 2006). 6 subjects 
receiving the new drug suffered a so-called “cytokine storm”, a sudden increase in pro-inflammatory 
cytokines resulting in severe cell and tissue destruction and loss of organ function (Suntharalingam 
et al., 2006). Whilst all subjects survived, review of the trial conduction let to worldwide changes in 
regulations of clinical trial conducts (Hunig, 2012).   
 
Cytokines and periodontal diseases 
The earliest cytokine studies in periodontal research can be dated back to the 1980s (Charon et al., 
1982; Mergenhagen, 1984) and coincide with the discovery of IL-1, IL-2 and TNF (Dinarello, 2007). 
These first studies were conducted using murine thymocyte bioassays. In these assays, thymocytes 
from mice were cultured and stimulated with GCF from inflamed or non-inflamed sites of human 
periodontitis patients. The results of the experiments showed increased thymocyte proliferation 
with GCF from inflamed sites compared to non-inflamed sites (Charon et al., 1982; Mergenhagen, 
1984). However, being non-specific, which factor(s) in GCF caused the proliferation remained 
undetermined. With the establishment of ELISAs IL-1 β was the first specifically measured cytokine in 
gingival tissue of patients with periodontal disease (Honig et al., 1989) and the field of studying 
cytokine concentrations in periodontal research using ELISAs multiplied from there. Other 
techniques such as immunohistochemistry and in situ hybridization (ISH) are used to investigate 
specifically the localization of cytokines at the protein or DNA/RNA level in gingival and periodontal 
tissues. However, acquisition of suitable tissues poses ethical complications as the aim of 
periodontitis treatment is to repair as much tissue as possible and additionally, the disease per se 
causes tissue destruction. Accurate quantification and suitable controls in these techniques 
therefore remains a challenge and ELISA clearly has the advantage in terms of high throughput, high 
reproducibility and relatively easy accessibility of oral fluids such as saliva or GCF. 
 
Utility of measurement of salivary cytokines in periodontitis 
Comparisons of cytokine concentrations between health and disease have been investigated for 
virtually any inflammatory condition and literature on this topic in periodontitis research is 
extensive. The aims of this research are to gain a better understanding of disease aetiology and 
susceptibility, to discover new treatment opportunities and to detect periodontitis early enough to 
avoid permanent tissue and bone destruction. Especially the last aim of detecting early changes of 
“biomarker” concentrations is of high importance in periodontal research as currently, there is no 
diagnostic method for periodontitis available other than a physical inspection of the oral cavity. 
Being able to identify the risk of developing periodontitis or very early stages of periodontitis and 
relapses would be an immense advantage to prevent permanent tissue and bone destruction. 
Additionally, the targeted anti-TNF α treatment in rheumatoid arthritis raised hopes that potentially 
a similarly effective drug treatment could be developed for periodontitis if the right target cytokine 
would be found.        
While early studies focused on serum and GCF samples for investigations of periodontitis related 
cytokines, saliva came into focus as an alternative sample in recent years and several manufacturers 
now offer ELISA kits specified for salivary detection of cytokines. Saliva has several advantages over 
GCF as it is easier accessible than GCF, can be sampled in a much larger volume and virtually 
anywhere and there is no special skill necessary for saliva sampling. Also, equally to GCF saliva gives 
a better representation of the local situation than analysis of serum. 
 
Considerations for biomarker identification 
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To evaluate if any of the below described salivary cytokines have potential as a periodontitis 
biomarker, it is necessary to first give a definition of what a biomarker is and what criteria it will be 
assessed on. The “Biomarkers Definitions Working Group” defines a biomarker as: “A characteristic 
that is objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention.” (Biomarkers 
Definitions Working, 2001). The quality of a biomarker should be assessed on a number of criteria, 
including study design (e.g. study quality) and statistical analysis (Lassere, 2008).  
Quality and design of the study 
Reviewing the current literature on analysis of salivary cytokines, potential methodological errors 
can be highlighted. For example, only few studies report calibrating procedures (reviewed in Hefti 
and Preshaw (2012)) for evaluating clinical parameters such as pocket depth (PD), clinical 
attachment loss (CAL) or bleeding on probing (BOP). Also, definitions of periodontitis or periodontal 
health groups appear to resemble more a lottery than a defined universal approach, with a total of 
16 different definitions found in 27 evaluated studies. The lack of uniformity in periodontitis 
definitions has been observed before (Preshaw, 2009) and makes it challenging to compare different 
study results. Another potential flaw in study design is the quality of the methodology to assess 
cytokine concentrations in saliva. Most research studies use commercially available ELISA kits for 
sample analysis, however none of them report any form of evaluation if these kits are suitable for 
analysis of saliva (despite manufacturers clearly indicating that any other sample type than the one 
specified for the kit has to be validated by the user themselves). ELISA validation procedures are well 
established in the literature and if successful, give great credibility to research results (Jaedicke et 
al., 2012). Whereas failing to validate an ELISA for the suitability with saliva samples can lead to 
erroneous results.    
 Statistical evaluation 
Whilst the majority of studies apply correct statistical analysis procedures, some common examples 
of statistical errors are made: Using parametric tests when data are not parametric, using dependent 
samples test when data are independent (for example paired samples t-test instead of Student’s 
independent sample t-test) or having a mixture of parametric and non-parametric tests (for example 
doing an ANOVA followed by Mann-Whitney-U comparisons). In addition, only few studies report a 
formal power calculation for sample size and likely many of the reviewed studies are underpowered. 
A key finding of this review was that although most studies did take normal distribution of their 
sample groups into account, the majority used the Kolmogorov–Smirnov test to assess normal 
distribution and only a minority of studies used the Shapiro-Wilk test. This is of concern as the 
Kolmogorov–Smirnov test is valid for a sample size of n>2000 whereas the Shapiro-Wilk test of 
normal distribution is valid for a smaller sample size, too and has superior statistical power (Razali 
and Wah, 2011).     
 
II Salivary cytokines in oral health and periodontal disease 
 
IL-1 family  
IL-1β (IL-1F2) undoubtedly is one of the most extensively studied cytokines in periodontitis and it is 
the one which is most referred to in salivary biomarker analysis. In general, IL-1β has a multitude of 
metabolic and immunological functions such as inducing fever and neutrophil development, 
activation of neutrophils, T-and B-cells and inducing liver acute phase protein release (reviewed in 
Dinarello, 2011). In periodontitis, IL-1β is recognised as an important inducer of other pro-
inflammatory cytokines, MMPs and chemokines. Additionally, it is associated with recruitment of 
PMNLs and activation of osteoclasts (Preshaw and Taylor, 2011). Seven out of the nine studies that 
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have investigated salivary IL-1β concentrations in periodontitis show a significant increase of IL-1β 
concentrations in periodontitis compared to healthy controls (see table 1). The other two studies do 
not report any significant changes. In addition, there are consistent findings that levels of salivary IL-
1β decrease after periodontal treatment (see table 1). Taking concentrations (mean±SD) described 
in the literature, salivary IL-1β concentrations in oral health range from 7.24±7.69 pg/ml (Ebersole et 
al., 2013) to 633±91 pg/ml (Teles et al., 2009). In periodontal disease, a range of 90.94±85.22 pg/ml 
(Ebersole et al., 2013) to 1312.75±691.22 pg/ml (Kaushik et al., 2011) can be found.  
Only a limited number of studies have investigated salivary concentrations of other members of the 
IL-1 family of cytokines in periodontitis. A study on IL-18 (IL-1F4) found increased concentrations in 
periodontitis patients (275.05±289.46 pg/ml) compared to healthy controls (143.71±103.68 pg/ml) 
(Ozcaka et al., 2011). IL-18 is secreted by a number of cell types (myeloid cells, keratinocytes, 
epithelial cells) and by activating neutrophils and Th1 cells potentially plays an important role in 
periodontal inflammation (reviewed in Barksby et al., (2007)). Salivary concentrations of IL-33 (IL-
1F11), an IL-1 family member which drives Th2 cytokine responses (Schmitz et al., 2005), appear to 
remain unaffected by periodontitis. Concentrations of 1.2±0.6 ng/ml and 1.1±0.5 ng/ml have been 
measured in periodontal health and disease, respectively (Buduneli et al., 2012).  
Nothing is known on salivary concentrations in systemically healthy patients with periodontitis of IL-
1 family members IL-1α (IL-1F1), IL-1RA (F3), F5, F6, F7, F8, F9 and F10. Except for IL-1β, no further 
information is available on post-treatment salivary concentrations of the IL-1 family of cytokines. 
 
 
IL-1β is highly relevant in periodontal disease etiology and with most studies consistently showing 
increased salivary IL-1β concentrations in periodontitis and decreased concentrations after 
periodontal treatment, this cytokine lends itself as a suitable periodontitis biomarker. In addition, 
reports show that its concentrations are not overly affected by systemic conditions or smoking (see 
section III and IV), making IL-1β a robust analyte. Furthermore, IL-1β concentrations in periodontitis 
are easily high enough to be detected by standard ELISA techniques, making widespread assays 
possible and avoiding the need for specialised centres. Both Ebersole et al.  (2013) and Ramseier et 
al. (2009) demonstrate potential of IL-1β to discriminate between periodontal health and disease 
with high specificity and sensitivity in ROC (receiver operator curve) analysis. Taken together, all 
evidence points towards changes in salivary IL-1β concentrations as a strong periodontitis 
biomarker. The only potential negative finding is a significant overlap of salivary IL-1β concentrations 
within healthy or periodontitis categories between studies (see table 1), which makes it difficult to 
compare results between different studies.   
TNF-α  
TNF-α is a key pro-inflammatory cytokine, produced mainly by macrophages and activated T cells as 
a first inflammatory response of TLR signalling (Bradley, 2008). TNF-α and RANKL both belong to the 
TNF superfamily and comparable to RANKL, TNF-α is a potent activator of osteoclasts and facilitates 
bone resorption (Romas et al., 2002). Several studies have investigated salivary TNF-α 
concentrations in periodontal health and disease (see table 1) however the levels detected are very 
small (health: 1.85±2.11 pg/ml; periodontitis: 5.44±10.88 pg/ml (Ebersole et al., 2013)). Out of seven 
studies only Frodge et al. (2008) report a significant increase in TNF-α concentrations in periodontitis 
compared to periodontal health, all other studies find no differences between the two groups (see 
table 1). After periodontal treatment, salivary TNF- α concentrations were reported to either 
decrease (Sexton et al., 2011) or stay the same (Kinney et al., 2011).  
Salivary TNF-α concentrations have been investigated numerous times however often 
concentrations were below level of detection and therefore not suitable as a biomarker. However, 
differences between periodontal health and disease were found when using highly sensitive 
detection methodology (Frodge et al., 2008) and therefore the potential of TNF-α as a periodontitis 
biomarker should be re-evaluated after more research with sensitive detection methodology is 
performed. 
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IL-6 
After induction by pro-inflammatory cytokines and stimuli such as IL-1β,TNF-α or LPS, IL-6 is 
produced by a variety of cell types, including lymphocytes, myeloid cells and epithelial cells 
(reviewed in Irwin and Myrillas (1998)). Together with other cytokines, IL-6 induces T-cell 
proliferation and, importantly for periodontitis, is associated with bone resorption and regulation of 
MMP activity (Irwin and Myrillas, 1998).  
In general, compared to for example salivary IL1-β concentrations, levels of IL-6 measured in saliva 
are low in both periodontal health (3.30±2.32 pg/ml) and disease (35.57±48.17 pg/ml) (Ebersole et 
al., 2013). Also, while some studies show that salivary IL-6 concentrations are significantly higher in 
periodontitis than in healthy individuals (Costa et al., 2010; Ebersole et al., 2013; Prakasam and 
Srinivasan, 2013), the majority of studies find no differences between the two groups (see table 1). 
Reports on post-treatment evaluations of salivary IL-6 concentrations show no significant changes 
(Kinney et al., 2011; Prakasam and Srinivasan, 2013). 
Therefore, IL-6 does not receive a positive outcome as a salivary periodontitis biomarker in 
evaluation of the current evidence. Concentrations of IL-6 are small, often no differences between 
periodontal health and disease are detected and no post-treatment differences can be found. 
 
 
IL-4 
IL-4 is mainly produced by T-cells, specifically the Th2 subset of T-cells. It has important functions in 
the regulation of cell proliferation and apoptosis in numerous cell types, including lymphocytes, 
myeloid cells, fibroblasts and epithelial cells (reviewed in Luzina et al., 2012). Findings for salivary 
concentrations of IL-4 are inconsistent. One study reports significantly lower levels in periodontitis 
compared to controls (Napimoga et al., 2011), another study reports significantly higher IL-4 
concentrations in periodontitis (Prakasam and Srinivasan, 2013) and two studies find no differences 
in salivary IL-4 concentrations between periodontal health and disease (Ramseier et al., 2009; Teles 
et al., 2009). In periodontal health, minimal levels of IL-4 can be detected (0.0 (0-5.315.1) pg/ml, 
given as median + range) and in periodontitis the amount is small as well (69.5 (0-11,714.3) pg/ml, 
given as median + range) (Ramseier et al., 2009). After periodontal treatment, salivary IL-4 
concentrations were shown to decrease or to not be affected (Kinney et al., 2011; Prakasam and 
Srinivasan, 2013).  
Considering the current evidence, the Th2 cytokine IL-4 is not a strong salivary periodontitis 
biomarker. Salivary IL-4 concentrations are small, often no differences between periodontal health 
and disease are detected and inconsistencies between studies evaluating post-treatment differences 
are seen. 
  
IL-10 
IL-10 is produced by a variety of cell types, including myeloid cells, T and B cells, NK-cells and 
neutrophils (reviewed in Ouyang et al., 2011). It is a key anti-inflammatory cytokine, involved in 
inhibiting and regulating pro-inflammatory immune responses and promoting resolution of 
inflammation (Ouyang et al., 2011). In comparison to IL-4, overall salivary IL-10 concentrations are 
considerably higher (periodontal health: 881.4 (0-11,088.8) pg/ml; periodontal disease: 1,445.1 (0-
30,633.1) pg/ml given as median + range)) (Ramseier et al., 2009). One study reports significantly 
lower levels in periodontitis compared to controls (Prakasam and Srinivasan, 2013), another study 
reports significantly higher IL-10 concentrations in periodontitis (Napimoga et al., 2011) and two 
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studies find no differences in salivary IL-10 concentrations between periodontal health and disease 
(Ramseier et al., 2009; Teles et al., 2009). Periodontal treatment does not appear to affect salivary 
IL-10 concentrations (Kinney et al., 2011; Prakasam and Srinivasan, 2013). 
In terms of the amount found, salivary IL-10 concentrations show somewhat more potential as a 
periodontitis biomarker than IL-6 or IL-4. Levels in saliva per se are higher and readily detected with 
standard ELISA techniques. However, study findings are inconsistent and no changes are detected 
after periodontal treatment (see table 1 and 2). 
 
IL-17 
The role of the many T cell subsets expressing for example “Th1” cytokines such as IL-2, IL-10 and 
IFN-γ, “Th2” cytokines such as IL-4, IL-5, IL-6 and IL-13 or “Th17” cells expressing IL-17 is still not 
completely understood in periodontal disease. Since the discovery of Th17 cells, the classic roles of 
Th1 cytokines driving the “early”, stable and reversible gingivitis lesions versus Th2 cytokines driving 
the “later”, progressive periodontal lesions has been challenged (Gaffen and Hajishengallis, 2008). In 
their review on T cell subsets in periodontitis, Gaffen and Hajishengallis (2008) convincingly outline 
that rather than simply employing the Th1/Th2 paradigm to explain cell mediated immune 
responses in periodontitis, studies should interpret old and new findings taking Th17 cells into 
account, creating an ever more complex picture of the disease.       
Although salivary IL-17 concentrations are minute in both periodontal health (2.9±0.82 pg/ml) and 
disease (2.22±1.87 pg/ml) (Ozcaka et al., 2011), both studies comparing health and disease IL-17 
levels find significantly lower concentrations in periodontitis compared to health (Ozcaka et al., 
2011; Prakasam and Srinivasan, 2013). However, these concentrations do not change after 
periodontal treatment (Prakasam and Srinivasan, 2013). There are currently not enough data 
available to judge if IL-17 is a suitable periodontitis biomarker. 
GM-CSF 
GM-CSF is a key haematopoietic growth factor and is produced by a variety of cell types, including 
macrophages and fibroblasts (Shi et al., 2006). In oral epithelial cells, it is induced in response to 
Candida infections (Li and Dongari-Bagtzoglou, 2009) and it is used as a drug against severe mucositis 
associated with radiotherapy during cancer treatment (Worthington et al., 2007). 
A study investigating salivary concentrations of GM-CSF reports no differences between periodontal 
health and disease (no concentrations available) (Teles et al., 2009). There are currently not enough 
data available to judge if GM-CSF is a suitable periodontitis biomarker. 
Other cytokines 
No differences between salivary concentrations of IL-2, IL-5, IL-13 or IFN-γ between periodontal 
health and disease can be detected and no changes in concentrations after periodontal treatment 
have been reported (see table 1 and 2). Salivary concentrations of other cytokines have not been 
investigated to date. 
 
RANKL and OPG 
The RANKL-OPG system has been the focus of many recent investigations in periodontal research. 
RANKL (receptor activator of NF-κB ligand) is produced mainly by osteoblasts, fibroblasts and 
activated T and B cells. When binding to its receptor RANK on pre-osteoclasts, it induces osteoclast 
differentiation and bone resorption. The decoy receptor OPG (osteoprotegerin) for RANKL is mainly 
produced by fibroblasts and through binding of RANKL inhibits osteoclastogenesis (reviewed in 
Belibasakis and Bostanci (2012)). Generally, it appears that RANKL is upregulated and OPG is 
downregulated in periodontal disease (Belibasakis and Bostanci, 2012). However, findings of salivary 
concentrations of OPG and RANKL in periodontal health and disease are not as clear. Out of seven 
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studies, only three (Buduneli et al., 2008; Tobon-Arroyave et al., 2012; Tabari et al., 2013) 
simultaneously measured salivary concentrations of OPG and RANKL. These studies show a 
significant increase in RANKL concentrations in periodontitis compared to oral health (health: 4.0 
(2.4-6.6) pg/ml, given as median+IQR; disease: 6.0 (2.7-11.1) pg/ml, given as median+IQR (Tobon-
Arroyave et al., 2012)) but only Tobon-Arroyave et al. (2012) show a decrease in OPG levels in 
periodontitis (95.2 (49.8-145.2) pg/ml, given as median+IQR) compared to periodontal health (131.6 
(82.2-202.4) pg/ml, given as median+IQR). Buduneli et al. (2008) and Tabari et al. (2013)  do not 
report any change in salivary OPG concentrations. Other studies report varied findings, showing both 
increases, decreases or no changes in salivary OPG and RANKL concentrations in periodontal health 
and disease (see table 1). Two studies have investigated post-treatment salivary concentrations of 
OPG and both find a significant reduction after periodontal treatment (Kinney et al., 2011; Sexton et 
al., 2011). Salivary concentrations of RANKL have not been investigated after periodontitis treatment 
to date. 
Judging from biomarker research studies in rheumatoid arthritis (van Tuyl et al., 2010) and the 
above discussed role in bone metabolism, salivary OPG and RANKL concentrations should be prime 
candidates as periodontitis biomarkers. However, salivary concentrations of both OPG and RANKL 
are relatively small and study results are inconsistent. It is noteworthy in this context that in our own 
laboratory a RANKL ELISA (BioSupply UK) failed standard validation procedures for saliva 
(unpublished observations). Since none of the evaluated studies state anything about testing 
suitability of their assays with saliva, potentially false positive or false negative detection of salivary 
OPG or RANKL concentrations could partly explain inconsistencies in findings between different 
studies. More data are needed to judge if RANKL and OPG are suitable periodontitis biomarkers. 
    
CRP 
The classical acute phase protein CRP has been investigated numerous times as a potential 
connection between periodontal inflammation and other systemic inflammatory conditions 
(Paraskevas et al., 2008). CRP is produced in the liver in response to pro-inflammatory cytokines 
such as IL-1β or IL-6 and acts as an activator of the complement system (Black et al., 2004). Most 
studies show an increase in salivary CRP concentrations between periodontal health (6.7±6.5 pg/ml) 
and disease (80.4±104.3 pg/ml) (Pederson et al., 1995) (see table 1). However, one study using 
radial-immuno diffusion to measure CRP concentrations reports significant lower CRP levels in 
periodontitis (Aurer et al., 2005). Post-treatment salivary CRP concentrations have not been 
investigated to date. 
Although most studies show increased salivary CRP concentrations in periodontitis compared to 
health, there is also evidence that smoking potentially is a confounding factor (see section IV). Taken 
together with the lack of post-treatment studies, currently salivary CRP concentrations are likely not 
the most suitable periodontitis biomarker. 
 
Chemokines  
Chemokines are produced by oral tissues in response to pro-inflammatory cytokines such as IL-1, 
TNF-α or IFN-γ and bacterial products such as LPS or fimbria (reviewed in Silva et al., 2007). 
Chemokines target a wide range of immune cells, including neutrophils, lymphocytes and 
macrophages to facilitate their recruitment to the site of inflammation and they are a key player in 
the pathogenesis of chronic periodontitis (Silva et al., 2007). 
Salivary concentrations of the neutrophil chemotactic factor IL-8 do not appear to be effected by 
periodontitis or periodontitis treatment (see table 1 and 2) and concentrations of 457±668 pg/ml 
and 664±1112 pg/ml have been reported for periodontal health and disease, respectively 
(Rathnayake et al., 2013b). Significantly higher salivary concentrations of the macrophage 
chemotactic factor MCP-1 (CCL2) and the Th1-cell chemotactic factor MIP1-α (CCL3) have been 
found in periodontitis compared to periodontal health (no concentrations available) (Al-Sabbagh et 
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al., 2012; Gupta et al., 2013). A decrease in salivary MCP-1 concentrations was found after 
periodontal treatment (Gupta et al., 2013) however no change was observed for MIP-1-α (Sexton et 
al., 2011). There are currently not enough data available to judge if either IL-8, MCP-1 or MIP-1-α are 
a suitable periodontitis biomarker. No further information is available on salivary concentrations of 
other chemokines. 
 
HGF 
HGF is a multifunctional growth factor, involved in several physiological processes such as tissue 
development, regeneration and wound healing. It enhances the production of MMPs and stimulates 
processes of wound healing such as vascularisation and keratinocyte proliferation (Matsumoto et al., 
1991; Dunsmore et al., 1996). In oral tissues, HGF is produced by periodontal ligament cells and 
gingival fibroblasts (Ohshima et al., 2001) in response to pro-inflammatory cytokines such as IL-1, 
TNF-α or PGE2 and bacterial LTA (Sugiyama et al., 1996; Ohnishi et al., 2000).  
Studies investigating salivary concentrations of HGF consistently report increased concentrations in 
periodontal disease (3430.8±1640.2 pg/ml) compared to periodontal health (443.82±295.14 pg/ml) 
(Rudrakshi et al., 2011) (see table 1). No further information is available on salivary concentrations 
of other growth factors.  
Although only few studies have investigated salivary HGF concentrations, together with our own 
findings (unpublished data) all study results are very consistent, with clear differences between 
periodontal health and disease. Salivary HGF concentrations have not been evaluated yet in a 
longitudinal study but the consistency of the findings highlight its potential as a periodontitis 
biomarker on a similar scale as IL-1β. 
 
Adipokines 
Adipokines are a loosely termed group of pro-and anti-inflammatory cytokines, growth factors, 
hormones and chemokines, their main common feature being production by adipose tissue, 
although they are produced by other tissues and cell types, too. Adipokines such as leptin, 
adiponectin, visfatin or resistin have lately received some attention in periodontitis research 
however only two papers investigating salivary visfatin and chemerin concentrations in periodontal 
health and disease have been published to date.  
Although visfatin can be secreted from adipocytes (Tanaka et al., 2007), main sources include 
immune cells such as macrophages, neutrophils and lymphocytes (Jia et al., 2004; Curat et al., 2006). 
Visfatin induces pro-inflammatory cytokines such as TNF-α, IL-6 or IL-1β in monocytes and 
fibroblasts and also acts as a chemoattractant for monocytes and B-cells (Brentano et al., 2007; 
Moschen et al., 2007). Together with other pro-inflammatory cytokines it therefore potentially plays 
an important role in periodontal disease. Chemerin is produced by several cell types, including 
adipocytes, fibroblasts and epithelial cells. True to its name, its key function is to act as a 
chemoattractant for various immune cells such as macrophages, dendritic cells and NK cells during 
inflammation (reviewed in Zabel et al. (2014)).  
Significantly higher salivary concentrations of visfatin and chemerin have been found in periodontitis 
compared to periodontal health (Ozcan et al., 2014; Tabari et al., 2014). Salivary concentrations of 
23.38±7.58 ng/ml and 33.43±15.72 ng/ml for visfatin and of 0.042 ng/ml and 0.084 ng/ml for 
chemerin have been reported for periodontal health and disease, respectively (Ozcan et al., 2014; 
Tabari et al., 2014). There are currently not enough data available to judge if any of the adipokines 
are a suitable periodontitis biomarker. 
III The effect of systemic diseases on salivary cytokine concentrations 
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Few studies have investigated the impact of systemic diseases on salivary cytokines in periodontitis 
and none have been designed with specifically this aim in mind. Therefore, one has to be cautious 
drawing too strong conclusions from the presented study results.   
Reports on salivary IL-1β concentrations in heart disease, hypertension, diabetes, inflammatory 
bowel disease or rheumatoid arthritis show no significant differences between patients and 
systemically healthy controls (Mirrielees et al., 2010; Yoon et al., 2012; Rathnayake et al., 2013a), 
even though oral health status was not always considered in the analysis (Rathnayake et al., 2013a). 
A comparable theme can be seen for salivary cytokines IL-6 and TNF-α, concentrations of both do 
not appear to be effected by systemic conditions (Aleksandra Nielsen et al., 2005; Costa et al., 2010; 
Mirrielees et al., 2010; Rathnayake et al., 2013a).  
An investigation on IL-1RA salivary concentrations in diabetes revealed lower concentrations in 
patients with periodontal disease than those with periodontal health (Chan et al., 2012). Since a 
non-diabetic control group was not included in this study, it is not possible to estimate whether local 
or systemic conditions influence salivary IL-1RA concentrations.   
Inflammatory bowel disease was associated with higher salivary IL-8 concentrations in one study, 
however since oral health status was not considered, it is not possible to evaluate local or systemic 
effects independently (Rathnayake et al., 2013a). Similar, an increase in salivary MCP-1 (CCL2) 
concentrations in Sjögren's syndrome cannot be accounted for without evaluation of oral health 
(Hernandez-Molina et al., 2011). The same study also investigated salivary MIP-1α concentrations 
and found no differences between patients with Sjögren's syndrome and systemically healthy 
controls (Hernandez-Molina et al., 2011).   
 
IV The effect of smoking on salivary cytokine concentrations 
 
Salivary concentrations of IL-1β and IL-6 do not appear to be effected by smoking (Nishida et al., 
2006; Rathnayake et al., 2013b), however these studies did not account for the periodontal status of 
either smokers or non-smokers. Assessing salivary IL-8 concentrations in the same study, Rathnayake 
et al. (2013b) report decreased concentrations in smokers compared to non-smokers, indicating that 
smoking potentially has an effect on this chemokine. 
Effects of smoking on salivary concentrations of RANKL and OPG have been investigated in two 
studies, with different outcomes. Tobon-Arroyave et al. (2012) find no difference in RANKL or OPG 
concentrations between smokers and non-smokers, however oral health was not taken into account. 
A study by Buduneli et al. (2008) reports lower salivary OPG concentrations in smokers with 
periodontitis than in non-smokers with periodontitis, indicating a possible effect of smoking on OPG 
concentrations. The same study does not find any differences in salivary RANKL concentrations 
between smokers and non-smokers (Buduneli et al., 2008).  
Lonn et al. (2014) do not account for smoking when they show increased salivary HGF 
concentrations in smokers with periodontitis than in a majority of non-smokers without 
periodontitis, making it impossible to elucidate effects of either periodontitis or smoking. 
After excluding self-reported periodontitis cases, Azar and Richard  (2011) conclude that salivary CRP 
concentrations are higher in smokers than in non-smokers.   
Considering the available data, it appears that overall systemic conditions or smoking only have a 
limited impact on salivary cytokine concentrations. However, more research which specifically aims 
to evaluate these relationships is needed to come to firm conclusions.  
V Concluding remarks 
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The present review demonstrates that saliva is a valid local source for investigating periodontal 
cytokines, with many advantages over other sources such as GCF. Care has to be taken when 
considering which methodology to choose for analysis, however commercial manufacturers of ELISA 
kits have picked up on the “saliva” trend and several assays are available. 
In conclusion, current evidence suggests that the two cytokines IL-1β and HGF are the most robust 
salivary periodontitis biomarkers. High quality research designs such as randomized controlled trials 
specifically targeting sensitivity and specificity and confounding factors such as smoking and 
systemic diseases should be the next step in salivary periodontitis biomarker research. This would 
help to evaluate if the biomarker knowledge can be implemented in a diagnostic test to detect 
periodontitis (or risk thereof) before permanent tissue and bone damage occurs.  
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Table 1: Cross-sectional analysis of salivary cytokine concentrations in systemically 
healthy subjects in periodontal health and disease 
Cytokine Concentration 
health 
Concentration 
disease 
Main findings 
IL-1 family 
IL-1β n=29 (ELISA, LOC 
lab-on-a-chip 
system)  (only 
graph, no 
numbers) 
CP n=28 (ELISA, LOC 
lab-on-a-chip 
system) (only graph, 
no numbers) 
significantly higher* 
significantly increased 
concentrations in 
periodontitis 
(Christodoulides et 
al., 2007) 
n=29  
212.8±167.4 pg/ml 
CP n=28  
753.7±1022.4 
pg/ml* 
significantly increased 
concentrations in 
periodontitis; 
significant positive 
correlation with BOP 
and CAL (Miller et al., 
2006) 
n=303  
61±87 pg/ml  
mild CP n=89 
82±109 pg/ml* 
severe CP n= 49 
144±220 pg/ml*  
 
significantly increased 
concentrations in 
both mild and severe 
periodontitis; 
significant positive 
correlation with BOP 
(Rathnayake et al., 
2013b)  
n=44  
633±91 (SEM) 
pg/ml 
CP n=74  
673±69 (SEM) pg/ml 
no difference 
between 
periodontitis and 
health, no significant 
correlation with BOP 
(Teles et al., 2009)   
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n=30  
7.24 ± 7.69 pg/ml 
CP n=50  
90.94 ± 85.22 
pg/ml* 
significantly increased 
concentrations in 
periodontitis 
(Ebersole et al., 2013) 
n=81  
467.8±279.8 pg/ml 
CP n=84  
665.7 ± 267.5 
pg/ml* 
significantly increased 
concentrations in 
periodontitis (Gursoy 
et al., 2009) 
n=24  
161.51±149.6 
pg/ml 
CP n=28  
1,312.75 ± 691.22 
pg/ml* 
significantly increased 
concentrations in 
periodontitis; 
significant positive 
correlation with BOP 
(Kaushik et al., 2011) 
 n=35  
(only graph, no 
numbers) 
CP n=35  
(only graph, no 
numbers)* 
significantly higher 
significantly increased 
concentrations in 
periodontitis 
(Mirrielees et al., 
2010) 
n=18 (healthy) 
158.6 (0 to 6,000) 
pg/ml (median + 
range) 
n= 23 (gingivitis)  
206.7 (0 to 3,856.8) 
pg/ml (median + 
range) 
 
n=28 (mild CP) 
247.5 (24.1 to 
3,120) pg/ml 
(median + range) 
n=21 (moderate-
severe PD) 
462.2 (15.7 to 
6,000) pg/ml 
(median + range) 
no difference 
between 
periodontitis and 
health (Ramseier et 
al., 2009) 
IL-18 (IL-1F4) 
 
n=21  
143.71±103.68 
pg/ml 
CP n=22  
275. 05±289.46 
pg/ml* 
significantly increased 
concentrations in 
periodontitis; 
significant positive 
correlation with BOP 
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(Ozcaka et al., 2011) 
IL-33 (IL-1F11) 
 
n=25  
1.2±0.6 ng/ml 
CP n=32  
1.1±0.5 ng/ml 
no difference 
between 
periodontitis and 
health, no significant 
correlation with BOP 
or CAL (Buduneli et 
al., 2012) 
Other Interleukins 
IL-2 
 
n=44  
(only graph, no 
numbers) 
CP n=74  
(only graph, no 
numbers) 
no difference 
between 
periodontitis and 
health, no significant 
correlation with BOP 
(Teles et al., 2009)   
 n=18 (healthy) 
0.0 (0 to 3,718.1) 
pg/ml (median + 
range) 
n= 23 (gingivitis)  
0.0 (0 to 6,000) 
pg/ml (median + 
range) 
 
n=28 (mild CP) 
8.0 (0 to 6,205.5) 
pg/ml (median + 
range) 
n=21 (moderate-
severe PD) 
0.0 (0 to 14,400.1)  
pg/ml (median + 
range) 
no difference 
between 
periodontitis and 
health (Ramseier et 
al., 2009) 
IL-4 
 
n=44  
(only graph, no 
numbers) 
CP n=74  
(only graph, no 
numbers) 
no difference 
between 
periodontitis and 
health, no significant 
correlation with BOP 
(Teles et al., 2009)   
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n=15  
(only graph, no 
numbers) 
CP n=15  
(only graph, no 
numbers)* 
significantly lower 
significantly 
decreased 
concentrations in 
periodontitis 
(Napimoga et al., 
2011) 
n=18 (healthy) 
0.0 (0 to 5,315.1) 
pg/ml (median + 
range) 
n= 23 (gingivitis)  
0.0 (0 to 6,579.3) 
pg/ml (median + 
range) 
 
n=28 (mild CP) 
54.4 (0 to 14,588) 
pg/ml (median + 
range) 
n=21 (moderate-
severe PD) 
69.5 (0 to 11,714.3) 
pg/ml (median + 
range) 
no difference 
between 
periodontitis and 
health (Ramseier et 
al., 2009) 
n=20  
(only graph, no 
numbers) 
CP n=20  
(only graph, no 
numbers)* 
significantly higher 
significantly increased 
concentrations in 
periodontitis 
(Prakasam and 
Srinivasan, 2013) 
IL-5 
 
n=44  
(only graph, no 
numbers) 
CP n=74  
(only graph, no 
numbers) 
no difference 
between 
periodontitis and 
health, no significant 
correlation with BOP 
(Teles et al., 2009)   
IL-6 n=22  
(only graph, no 
numbers)   
CP n=24  
(only graph, no 
numbers)* 
significantly higher 
significantly increased 
concentrations in 
periodontitis (Costa 
et al., 2010)   
 n=303  
8.0±12 pg/ml  
mild CP n=89 
7.4±6.9 pg/ml 
severe CP n= 49 
no difference 
between 
periodontitis and 
health, no significant 
correlation with BOP 
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8.4±14.3 pg/ml  (Rathnayake et al., 
2013b)  
 n=44  
(only graph, no 
numbers) 
CP n=74  
(only graph, no 
numbers) 
no difference 
between 
periodontitis and 
health, no significant 
correlation with BOP 
(Teles et al., 2009)   
 
 
   
 n=30  
3.30 ± 2.32 pg/ml 
CP n=50  
35.57 ± 48.17 
pg/ml* 
significantly increased 
concentrations in 
periodontitis 
(Ebersole et al., 2013) 
 n=81  
3.1 ± 3.6 pg/ml 
CP n=84  
3.6 ±5.9 pg/ml 
no difference 
between 
periodontitis and 
health (Gursoy et al., 
2009) 
 n=18 (healthy) 
0.0 (0 to 1,915) 
pg/ml (median + 
range) 
n= 23 (gingivitis)  
22.1 (0 to 8,784.9)  
pg/ml (median + 
range) 
n=28 (mild CP) 
14.6 (0 to 5,259.7) 
pg/ml (median + 
range) 
n=21 (moderate-
severe PD) 
88.7 (0 to 10,816.9) 
pg/ml (median + 
range) 
no difference 
between 
periodontitis and 
health (Ramseier et 
al., 2009) 
 n=20  
(only graph, no 
numbers) 
CP n=20  
(only graph, no 
numbers)* 
significantly higher 
significantly increased 
concentrations in 
periodontitis 
(Prakasam and 
Srinivasan, 2013) 
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IL-10 n=44  
(only graph, no  
numbers) 
CP n=74  
(only graph, no  
numbers) 
no difference 
between 
periodontitis and 
health, significant 
negative correlation 
with BOP (Teles et al., 
2009)   
 n=15  
(only graph, no 
numbers) 
CP n=15  
(only graph, no 
numbers)* 
significantly higher 
significantly increased 
concentrations in 
periodontitis 
(Napimoga et al., 
2011) 
 n=18 (healthy) 
881.4 (0 to 
11,088.8) pg/ml 
(median + range) 
n= 23 (gingivitis)  
120.6 (0 to 
45,488.9) pg/ml 
(median + range) 
 
n=28 (mild CP) 
1,153.1 (0 to 
24,581.4) pg/ml 
(median + range) 
n=21 (moderate-
severe PD) 
1,445.1 (0 to 
30,633.1) pg/ml 
(median + range) 
no difference 
between 
periodontitis and 
health (Ramseier et 
al., 2009) 
 n=20  
(only graph, no 
numbers) 
CP n=20  
(only graph, no 
numbers)* 
significantly lower 
significantly 
decreased 
concentrations in 
periodontitis 
(Prakasam and 
Srinivasan, 2013) 
IL-13 n=18 (healthy) 
14.3 (0 to 83,151.1) 
pg/ml (median + 
range) 
n= 23 (gingivitis)  
0.0 (0 to 92,423.8) 
pg/ml (median + 
n=28 (mild CP) 
0.0 (0 to 76,046) 
pg/ml (median + 
range) 
n=21 (moderate-
severe PD) 
169.9 (0 to 
75,445.2) pg/ml 
no difference 
between 
periodontitis and 
health (Ramseier et 
al., 2009) 
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range) 
 
(median + range) 
IL-17 
 
n=20  
(only graph, no 
numbers) 
CP n=20  
(only graph, no 
numbers)* 
significantly lower 
significantly 
decreased 
concentrations in 
periodontitis 
(Prakasam and 
Srinivasan, 2013) 
 n=21  
2.9±0.82 pg/ml 
CP n=22  
2.22±1.87 pg/ml* 
significantly 
decreased 
concentrations in 
periodontitis; no 
correlation with BOP 
(Ozcaka et al., 2011) 
IFN-γ n=44  
(only graph, no 
numbers) 
CP n=74  
(only graph, no 
numbers) 
no difference 
between 
periodontitis and 
health, no significant 
correlation with BOP 
(Teles et al., 2009)   
    
RANKL and OPG 
OPG   on CP maintenance 
therapy n=22  
CP (pre-treatment) 
n=33  
(only graph, no 
numbers) 
no difference 
between patients on 
periodontitis 
maintenance therapy 
and periodontitis 
patients (Buduneli et 
al., 2008) 
 
n=22  
(only graph, no 
numbers)   
CP n=24  
(only graph, no 
numbers) 
no difference 
between periodontitis 
and health (Costa et 
al., 2010)   
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 n=29  
2.6±1.37 pmol/l  
CP n=28  
3.6±2.58 pmol/l 
no difference 
between periodontitis 
and health, significant 
positive correlation 
with BOP but not with 
CAL (Miller et al., 
2006) 
 n=43  
131.6 (82.2-202.4) 
pg/ml (median + 
interquartile range) 
CP n=97  
95.2 (49.8-145.2) 
pg/ml* (median + 
interquartile range) 
significantly 
decreased 
concentrations in 
periodontitis; 
significant negative 
correlation with CAL 
(Tobon-Arroyave et 
al., 2012)   
n=40  
(only graph, no 
numbers) 
CP n=40  
(only graph, no 
numbers) significantly 
higher* 
significantly increased 
concentrations in 
periodontitis; 
significant positive 
correlation with BOP 
and with CAL (Al-
Sabbagh et al., 2012) 
 n=18 (healthy) 
2.3 (1.4 to 6.6) pg/ml 
(median + range) 
n= 23 (gingivitis)  
2.7 (1.2 to 6.2) pg/ml 
(median + range) 
 
n=28 (mild CP) 
1.9 (0.2 to 10.1) pg/ml 
(median + range) 
n=21 (moderate-
severe PD) 
1.6 (0.5 to 11.8) pg/ml 
(median + range) 
* significantly lower 
significantly 
decreased 
concentrations in 
periodontitis 
(Ramseier et al., 2009) 
n=25 (healthy) 
2.1±1.0 pg/ml 
(median + IQR) 
 
n=25 (CP) 
2.2 ±0.7 pg/ml 
(median + IQR) 
no difference 
between periodontitis 
and health (Tabari et 
al., 2013) 
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RANKL (OPG-l)  n=21  
0.68±0.96 (SEM) 
pmol/l  
CP n=21  
1.15±0.25 (SEM) 
pmol/l 
no difference 
between periodontitis 
and health (Frodge et 
al., 2008) 
  on CP maintenance 
therapy n=22  
CP (pre-treatment) 
n=33  
(only graph, no 
numbers)  
significantly higher 
pre-treatment* 
significantly higher 
concentrations in 
periodontitis patients 
than in patients on 
periodontitis 
maintenance therapy 
(Buduneli et al., 2008) 
 
 n=43  
4.0 (2.4–6.6) pg/ml 
(median + 
interquartile range)  
CP n=97  
6.0 (2.7–11.1) pg/ml* 
(median + 
interquartile range) 
significantly increased 
concentrations in 
periodontitis; 
significant positive 
correlation with CAL 
(Tobon-Arroyave et 
al., 2012)   
 n=25 (healthy) 
207±83 pg/ml 
(median + IQR) 
 
n=25 (CP) 
266 ±48 pg/ml* 
(median + IQR) 
significantly increased 
concentrations in 
periodontitis; 
significant positive 
correlation with CAL 
(Tabari et al., 2013) 
TNF-α  
TNF-α n=14 ELISA below 
level of detection 
CP n=10 ELISA 
below level of 
detection 
AgP n=9 ELISA 
below level of 
detection 
no TNF-α was 
detected (Aurer et al., 
2005) 
 n=39  
2.03±0.49 (SEM) 
CP n=35  
4.33±0.73 (SEM) 
significantly increased 
concentrations in 
periodontitis (Frodge 
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pg/ml  pg/ml* et al., 2008) 
n=44  
(only graph, no 
numbers) 
CP n=74  
(only graph, no 
numbers) 
no difference 
between 
periodontitis and 
health, no significant 
correlation with BOP 
(Teles et al., 2009)   
    
n=30  
1.85 ± 2.11 pg/ml 
CP n=50  
5.44 ± 10.88 pg/ml 
no difference 
between 
periodontitis and 
health (Ebersole et 
al., 2013) 
 n=81  
2.7 ± 2.8 pg/ml 
CP n=84  
2.9 ± 4.0 pg/ml 
no difference 
between 
periodontitis and 
health (Gursoy et al., 
2009) 
n=35  
(only graph, no 
numbers) 
CP n=35  
(only graph, no 
numbers) 
no difference 
between 
periodontitis and 
health (Mirrielees et 
al., 2010) 
 n=18 (healthy) 
9.8 (0 to 1,788.3) 
pg/ml (median + 
range) 
n= 23 (gingivitis)  
0.0 (0 to 3,720.5) 
pg/ml (median + 
range) 
 
n=28 (mild CP) 
8.1 (0 to 4,370.2) 
pg/ml (median + 
range) 
n=21 (moderate-
severe PD) 
0.0 (0 to 8,212.7) 
pg/ml (median + 
range) 
no difference 
between 
periodontitis and 
health (Ramseier et 
al., 2009) 
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CRP    
 n=14 (no ELISA, 
radial-immuno 
diffusion) 
90.20±79.67 (no 
unit given) 
CP n=10 (no ELISA, 
radial-immuno 
diffusion) 
27.45±29.59* (no 
unit given) 
AgP n=9 (no ELISA, 
radial-immuno 
diffusion) 
102.11±79.02 (no 
unit given) 
significantly 
decreased 
concentrations in 
chronic periodontitis, 
no difference to 
aggressive 
periodontitis (Aurer 
et al., 2005) 
 n=15 (no ELISA, 
ETC lab-on-a-chip 
system) 92 pg/ml  
CP n=15 (no ELISA, 
LOC lab-on-a-chip 
system) 2001 
pg/ml* 
 
significantly increased 
concentrations in 
periodontitis 
(Christodoulides et 
al., 2005) 
 n=29 (not detected 
in ELISA, LOC lab-
on-a-chip system) 
(only graph, no 
numbers) 
CP n=28 (not 
detected in ELISA, 
LOC lab-on-a-chip 
system (only graph, 
no numbers) 
significantly higher* 
significantly increased 
concentrations in 
periodontitis 
(Christodoulides et 
al., 2007) 
 n=5  
6.7±6.5 pg/ml  
mild-moderate CP 
n=18  
43.4±49.6 pg/ml*  
moderate-severe CP 
n=8  
80.4±104.3 pg/ml* 
significantly increased 
concentrations in 
periodontitis 
(Pederson et al., 
1995)  
Chemokines 
IL-8 (CXCL8) n=303  
457±668 pg/ml  
mild CP n=89 
575±532 pg/ml 
severe CP n= 49 
no difference 
between 
periodontitis and 
health, significant 
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664±1112 pg/ml  positive correlation 
with BOP 
(Rathnayake et al., 
2013b)  
 
 
n=44  
1945±181 (SEM) 
pg/ml 
CP n=74  
2268±111 (SEM) 
pg/ml 
no difference 
between 
periodontitis and 
health, significant 
positive correlation 
with BOP (Teles et al., 
2009)   
MIP1-α (CCL3) 
 
n=40  
(only graph, no 
numbers) 
CP n=40  
(only graph, no 
numbers) 
significantly higher* 
significantly increased 
concentrations in 
periodontitis; 
significant positive 
correlation with BOP 
and with CAL (Al-
Sabbagh et al., 2012) 
MCP-1 (CCL2)    
n=15  
(only graph, no 
numbers) 
CP n=30  
(only graph, no 
numbers) 
significantly higher* 
significantly increased 
concentrations in 
periodontitis; 
significant positive 
correlation with CAL 
(Gupta et al., 2013)  
   
Adipokines 
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Chemerin n=23  
0.042 (0.023-0.063) 
ng/ml (median + 25-
75%)  
gingivitis n=24  
0.042 (0.042-0.063) 
ng/ml (median + 25-
75%) 
 
CP n=25  
0.084 (0.063-0.105) 
ng/ml (median + 25-
75%)* 
significantly increased 
concentrations in 
periodontitis; significant 
positive correlation with 
CAL (Ozcan et al., 2014) 
Visfatin n=20  
23.38±7.58 ng/ml 
CP n=20  
33.43±15.72 ng/ml* 
significantly increased 
concentrations in 
periodontitis; significant 
positive correlation with 
CAL (Tabari et al., 2014) 
n=23  
267 (125-616) ng/ml 
(median + 25-75%)  
gingivitis n=24  
791 (267-1127) ng/ml 
(median + 25-75%)* 
 
CP n=25  
589 (302-1195) ng/ml 
(median + 25-75%)* 
significantly increased 
concentrations in both 
gingivitis and 
periodontitis; no 
significant correlation 
with CAL (Ozcan et al., 
2014) 
Growth factors  
GM-CSF n=44  
(only graph, no 
numbers) 
CP n=74  
(only graph, no 
numbers) 
no difference 
between 
periodontitis and 
health, no significant 
correlation with BOP 
(Teles et al., 2009)   
HGF n=12  
443.82±295.14 
pg/ml 
moderate CP n=12  
1878.99±1713.54 
pg/ml* 
significantly increased 
concentrations in 
periodontitis; 
significant positive 
correlation with BOP, 
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severe CP n=12  
3430.8±1640.2 
pg/ml* 
no significant 
correlation with CAL 
(Rudrakshi et al., 
2011) 
   
n=20  
0.68 (0-7.33) 
median (range) 
ng/ml 
CP n=26  
1.87±1.32 ng/ml* 
0.06-5.38 ng/ml 
(range) 
significantly increased 
concentrations in 
periodontitis; 
significant positive 
correlation with BOP, 
no significant 
correlation with CAL 
(Wilczynska-
Borawska et al., 
2006)  
   
 
 
 
Table 2: Longitudinal analysis of salivary cytokine concentrations in systemically 
healthy subjects before and after periodontal treatment 
Cytokine Concentration pre-
treatment 
Concentration post-
treatment 
Main findings 
IL-1 family 
IL-1β CP, n=24  
(only graph, no 
numbers)   
12 months later 
(only graph, no 
numbers)* 
significantly lower 
significantly 
decreased 
concentration after 
periodontal 
treatment (Kinney et 
al., 2011)  
CP, n=34  
(only graph, no 
7 months later 
(only graph, no 
significantly 
decreased 
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numbers)   numbers)* 
significantly lower 
concentration after 
periodontal 
treatment (Sexton et 
al., 2011)    
 CP n=28  
1,312.75 ± 691.22 
pg/ml 
1 month later 
674.34±480.89 
pg/ml* 
significantly 
decreased 
concentration after 
periodontal 
treatment (Kaushik et 
al., 2011) 
Other Interleukins 
IL-2 
 
CP n=24 
(only graph, no 
numbers) 
12 months later 
no difference 
(only graph, no 
numbers) 
concentrations are 
not effected by 
periodontal 
treatment (Kinney et 
al., 2011)  
IL-4 
 
CP n=24 
(only graph, no 
numbers) 
12 months later 
no difference 
(only graph, no 
numbers) 
concentrations are 
not effected by 
periodontal 
treatment (Kinney et 
al., 2011) 
 CP n= 20 
(only graph, no 
numbers) 
6 weeks later 
significantly lower* 
(only graph, no 
numbers) 
significantly 
decreased 
concentration after 
periodontal 
treatment (Prakasam 
and Srinivasan, 2013) 
IL-5 
 
CP n=24 
(only graph, no 
numbers) 
12 months later 
no difference 
(only graph, no 
numbers) 
concentrations are 
not effected by 
periodontal 
treatment (Kinney et 
al., 2011) 
IL-6 CP n=24 
(only graph, no 
12 months later concentrations are 
not effected by 
periodontal 
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numbers) no difference 
(only graph, no 
numbers) 
treatment (Kinney et 
al., 2011) 
 CP n= 20 
(only graph, no 
numbers) 
6 weeks later (only 
graph, no numbers) 
no difference 
 
concentrations are 
not effected by 
periodontal 
treatment (Prakasam 
and Srinivasan, 2013) 
IL-10 
 
CP n=24 
(only graph, no 
numbers) 
12 months later 
no difference 
(only graph, no 
numbers) 
concentrations are 
not effected by 
periodontal 
treatment (Kinney et 
al., 2011) 
 CP n= 20 
(only graph, no 
numbers) 
6 weeks later (only 
graph, no numbers) 
no difference 
 
concentrations are 
not effected by 
periodontal 
treatment (Prakasam 
and Srinivasan, 2013) 
IL-17 
 
CP n= 20 
(only graph, no 
numbers) 
6 weeks later (only 
graph, no numbers) 
no difference 
 
concentrations are 
not effected by 
periodontal 
treatment (Prakasam 
and Srinivasan, 2013) 
IFN-γ CP n=24 
(only graph, no 
numbers) 
12 months later 
no difference 
(only graph, no 
numbers) 
concentrations are 
not effected by 
periodontal 
treatment (Kinney et 
al., 2011) 
TNF-α CP n=24 
(only graph, no 
numbers) 
12 months later 
no difference 
(only graph, no 
numbers) 
concentrations are 
not effected by 
periodontal 
treatment (Kinney et 
al., 2011) 
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 CP, n=34  
(only graph, no 
numbers)   
7 months later 
(only graph, no 
numbers)* 
significantly lower 
significantly 
decreased 
concentration after 
periodontal 
treatment (Sexton et 
al., 2011)    
OPG  
OPG CP, n=24  
(only graph, no 
numbers)   
12 months later 
(only graph, no 
numbers)* 
significantly lower 
significantly 
decreased 
concentration after 
periodontal 
treatment (Kinney et 
al., 2011)  
 CP, n=34  
(only graph, no 
numbers)   
7 months later 
(only graph, no 
numbers)* 
significantly lower 
significantly 
decreased 
concentration after 
periodontal 
treatment (Sexton et 
al., 2011)    
Chemokines 
IL-8 (CXCL8) CP, n=34  
(only graph, no 
numbers)   
7 months later 
(only graph, no 
numbers)  
no difference 
concentrations are 
not effected by 
periodontal 
treatment (Sexton et 
al., 2011)    
MIP1-α (CCL3) 
 
CP, n=34  
(only graph, no 
numbers)   
7 months later 
(only graph, no 
numbers)  
no difference 
concentrations are 
not effected by 
periodontal 
treatment (Sexton et 
al., 2011)    
MCP-1 (CCL2) CP n=30  
 (only graph, no 
numbers) 
 1/1/2 months later 
(only graph, no 
numbers) 
significantly lower* 
significantly 
decreased 
concentration after 
periodontal 
treatment (Gupta et 
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al., 2013)  
 
 
 
 
 
